African trials in chemotherapy of gastrointestinal cancer.
Bleomycin either alone or in combination with radiotherapy was used in the treatment of 24 patients with non-resectable cancer of the oesophagus. Improvement in performance (swallowing) status was observed in 75% of patients, although only 19% were known to be alive after 1 year of follow-up. Patients with liver cancer were treated with adriamycin. The response rate was dose dependent and was 40% at best. Combination of adriamycin with other drugs did not improve the response rate. Intra-arterial adriamycin appears more efficacious and gave a response rate of 60%.
D000349:Africa; D001761:Bleomycin / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy
D001761:Bleomycin; D004317:Doxorubicin